Suchergebnisse - "Kong, Xiao"

PubPharm (29)

1

Serological Investigation of Persistent Villous Atrophy in Celiac Disease

enthalten in: Clinical and translational gastroenterology | 2023

von Gong, C. | Saborit, C. | Long, X. | +8

2

Human CARMIL2 deficiency underlies a broader immunological and clinical phenotype than CD28 deficiency

enthalten in: The Journal of experimental medicine | 2023

von Lévy, R. | Gothe, F. | Momenilandi, M. | +118

3

Inherited human ITK deficiency impairs IFN-γ immunity and underlies tuberculosis

enthalten in: The Journal of experimental medicine | 2023

von Ogishi, M. | Yang, R. | Rodriguez, R. | +41

4

Individuals with Down syndrome hospitalized with COVID-19 have more severe disease

enthalten in: Genetics in medicine : official journal of the American College of Medical Genetics | 2021

von Malle, L. | Gao, C. | Hur, C. | +5

5

Three Copies of Four Interferon Receptor Genes Underlie a Mild Type I Interferonopathy in Down Syndrome

enthalten in: Journal of clinical immunology | 2020

von Kong, X. | Worley, L. | Rinchai, D. | +24

6

Mendelian susceptibility to mycobacterial disease : 2014-2018 update

enthalten in: Immunology and cell biology | 2019

von Rosain, J. | Kong, X. | Martinez-Barricarte, R. | +7

7

Human IFN-γ immunity to mycobacteria is governed by both IL-12 and IL-23

enthalten in: Science immunology | 2018

von Martínez-Barricarte, R. | Markle, J. | Ma, C. | +50

8

A purely quantitative form of partial recessive IFN-γR2 deficiency caused by mutations of the initiation or second codon

enthalten in: Human molecular genetics | 2018

von Oleaga-Quintas, C. | Deswarte, C. | Moncada-Vélez, M. | +15

ErratumIn: Hum Mol Genet. 2019 Feb 1;28(3):524. - PMID 30329057

9

Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency

enthalten in: Nature immunology | 2018

von Kong, X. | Martinez-Barricarte, R. | Kennedy, J. | +38

CommentIn: Nat Immunol. 2018 Sep;19(9):906-907. - PMID 30127437

10

Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma : interim results and correlations with CD4+ T-lymphocyte counts

enthalten in: CNS oncology | 2018

von Bota, D. | Chung, J. | Dandekar, M. | +12